Novo Nordisk A/S
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 77,406
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Novo Alle 1 Bagsvaerd CR Denmark 2880
- IPO Date
- Apr 30, 1981
- CIK
- 0000353278
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?
As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize
Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads
Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now
Established Firm Harding Loevner Enters ETF Market With LOEV for International Investors
Crux Collaborates with Novo Nordisk to Offer Access to Wegovy® and Other Obesity Management Medications
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
Weight loss drugs linked to increase risk of hair loss
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
Novo Resources Releases Updated Corporate Presentation
The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side
NVO Challenges LLY Ads in GLP-1 Battle: Why the Lawsuit Matters Now
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly.
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Sues Rival Lilly Over Weight-Loss Ads
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?